Epidermolysis bullosa simplex (EBS) is a rare mechanobullous disease caused by dominant-negative mutations in either keratin 5 (KRT5) or keratin 14 (KRT14) genes. Until now, there is no cure for EBS and the care is primarily palliative. The discovery of the clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 system raised hope for the treatment of EBS and many other autosomal dominant diseases by mutant allele-specific gene disruption. In this study, we aim to disrupt the mutant allele for the heterozygous EBS pathogenic variation c.449T>C (p.Leu150Pro) within KRT5. This mutation generates, naturally, a novel protospacer-adjacent motif for the endonuclease Streptococcus pyogenes Cas9. Thus, we designed a single-guide RNA that guides the Cas9 to introduce a DNA cleavage of the mutant allele in patient's keratinocytes. Then, transfected cells were single-cell cloned and analyzed by deep sequencing. The expression of KRT5 and KRT14 was quantified, and the keratin intermediate filament stability was assessed. Results showed successful stringent mutant allele-specific knockout. An absence of synthesis of mutant transcript was further confirmed indicating permanent mutant allele-specific inactivation. Edited EBS patient keratinocytes produced a lower amount of K5 and K14 proteins compared with nonedited EBS cells, and no disturbance of cellular properties was observed.
BollingMC, LemminkHH, JansenGH, et al.Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75% of the patients. Br J Dermatol. 2011; 164:637–644. DOI: 10.1111/j.1365–2133.2010.10146.x
3.
PfendnerEG, BrucknerAL. Epidermolysis bullosa simplex. In: GeneReviews®. (Adam MP, Ardinger HH, Pagon RA, et al.; eds). Seattle, WA: University of Washington, Seattle.1993.
4.
FineJD, Bruckner-TudermanL, EadyRA, et al.Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014; 70:1103–1126. DOI: 10.1016/j.jaad.2014.01.903
5.
FineJD, BauerEA, BriggamanRA, et al.Revised clinical and laboratory criteria for subtypes of inherited epidermolysis bullosa. A consensus report by the Subcommittee on Diagnosis and Classification of the National Epidermolysis Bullosa Registry. J Am Acad Dermatol., 1991; 24:119–135. DOI: 10.1016/0190-9622(91)70021-s
HornHM, PriestleyGC, EadyRA, et al.The prevalence of epidermolysis bullosa in Scotland. Br J Dermatol. 1997; 136:560–564.
8.
FuchsE, CoulombeP, ChengJ, et al.Genetic bases of epidermolysis bullosa simplex and epidermolytic hyperkeratosis. J Invest Dermatol. 1994; 103:25S–30S. DOI: 10.1111/1523–1747.ep12398924
9.
CoulombePA, KernsML, FuchsE. Epidermolysis bullosa simplex: A paradigm for disorders of tissue fragility. J Clin Invest. 2009; 119:1784–1793. DOI: 10.1172/JCI38177
10.
SzeverenyiI, CassidyAJ, ChungCW, et al.The human intermediate filament database: Comprehensive information on a gene family involved in many human diseases. Hum Mutat. 2008; 29:351–360. DOI: 10.1002/humu.20652
11.
BanerjeeS, WuQ, YuP, et al.In silico analysis of all point mutations on the 2B domain of K5/K14 causing epidermolysis bullosa simplex: A genotype-phenotype correlation. Mol Biosyst. 2014; 10:2567–2577. DOI: 10.1039/c4mb00138a
12.
ZhangJ, DingY, LiM, et al.Known and novel mutations responsible for epidermolysis bullosa simplex cases in a Chinese population. Exp Ther Med. 2019; 18:4661–4664. DOI: 10.3892/etm.2019.8130
13.
ShinJW, KimKH, ChaoMJ, et al.Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9. Hum Mol Genet. 2016; 25:4566–4576. DOI: 10.1093/hmg/ddw286
GiannelliSG, LuoniM, CastoldiV, et al. Cas9/sgRNA selective targeting of the P23H rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery. Hum Mol Genet. 2018;27:761–779. DOI: 10.1093/hmg/ddx438
16.
PavaniG, FabianoA, LaurentM, et al.Correction of beta-thalassemia by CRISPR/Cas9 editing of the alpha-globin locus in human hematopoietic stem cells. Blood Adv. 2021; 5:1137–1153. DOI: 10.1182/bloodadvances.2020001996
17.
PatriziC, LladoM, BenatiD, et al.Allele-specific editing ameliorates dominant retinitis pigmentosa in a transgenic mouse model. Am J Hum Genet. 2021; 108:295–308. DOI: 10.1016/j.ajhg.2021.01.006
18.
BchetniaM, TremblayML, LeclercG, et al.Expression signature of epidermolysis bullosa simplex. Hum Genet. 2012; 131:393–406. DOI: 10.1007/s00439-011-1077-7
19.
WebberBR, OsbornMJ, McElroyAN, et al.CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. NPJ Regen Med. 2016; 1. DOI: 10.1038/npjregenmed.2016.14
20.
BrinkmanEK, ChenT, AmendolaM, et al.Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014; 42:e168. DOI: 10.1093/nar/gku936
21.
ConcordetJP, HaeusslerM. CRISPOR: Intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res. 2018; 46:W242–W245. DOI: 10.1093/nar/gky354
22.
RobinsonJT, ThorvaldsdottirH, WengerAM, et al.Variant review with the integrative genomics viewer. Cancer Res. 2017; 77:e31–e34. DOI: 10.1158/0008-5472.CAN-17-0337
23.
ClementK, ReesH, CanverMC, et al.CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol. 2019; 37:224–226. DOI: 10.1038/s41587-019-0032-3
24.
AushevM, KollerU, MussolinoC, et al.Traceless targeting and isolation of gene-edited immortalized keratinocytes from epidermolysis bullosa simplex patients. Mol Ther Methods Clin Dev. 2017; 6:112–123. DOI: 10.1016/j.omtm.2017.06.008
25.
BadowskiC, TanTS, AlievT, et al.Detrimental effects of IFN-gamma on an epidermolysis bullosa simplex cell model and protection by a humanized anti-IFN-gamma monoclonal antibody. JID Innov. 2022; 2:100096. DOI: 10.1016/j.xjidi.2022.100096
26.
TaylorSC, BerkelmanT, YadavG, et al.A defined methodology for reliable quantification of Western blot data. Mol Biotechnol. 2013; 55:217–226. DOI: 10.1007/s12033-013-9672-6
27.
CongL, RanFA, CoxD, et al.Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339:819–823. DOI: 10.1126/science.1231143
28.
DeverDP, BakRO, ReinischA, et al.CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature. 2016; 539:384–389. DOI: 10.1038/nature20134
RussellS, BennettJ, WellmanJA, et al.Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. Lancet. 2017; 390:849–860. DOI: 10.1016/S0140-6736(17)31868-8
31.
SlaymakerIM, GaoL, ZetscheB, et al.Rationally engineered Cas9 nucleases with improved specificity. Science. 2016; 351:84–88. DOI: 10.1126/science.aad5227
32.
ChristieKA, RobertsonLJ, ConwayC, et al.Mutation-independent allele-specific editing by CRISPR-Cas9, a novel approach to treat autosomal dominant disease. Mol Ther. 2020; 28:1846–1857. DOI: 10.1016/j.ymthe.2020.05.002
33.
LatellaMC, Di SalvoMT, CocchiarellaF, et al.In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR/Cas9 in the mouse retina. Mol Ther Nucleic Acids. 2016; 5:e389. DOI: 10.1038/mtna.2016.92
34.
LiP, KleinstiverBP, LeonMY, et al.Allele-specific CRISPR-Cas9 genome editing of the single-base P23H mutation for rhodopsin-associated dominant retinitis pigmentosa. CRISPR J. 2018; 1:55–64. DOI: 10.1089/crispr.2017.0009
35.
GyorgyB, Nist-LundC, PanB, et al.Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss. Nat Med. 2019; 25:1123–1130. DOI: 10.1038/s41591-019-0500-9
36.
LuanXR, ChenXL, TangYX, et al.CRISPR/Cas9-mediated treatment ameliorates the phenotype of the epidermolytic palmoplantar keratoderma-like mouse. Mol Ther Nucleic Acids. 2018; 12:220–228. DOI: 10.1016/j.omtn.2018.05.005
ChamcheuJC, LorieEP, AkgulB, et al.Characterization of immortalized human epidermolysis bullosa simplex (KRT5) cell lines: trimethylamine N-oxide protects the keratin cytoskeleton against disruptive stress condition. J Dermatol Sci. 2009; 53:198–206. DOI: 10.1016/j.jdermsci.2008.11.003
39.
AtkinsonSD, McGilliganVE, LiaoH, et al.Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. J Investig Dermatol. 2011; 131:2079–2086. DOI: 10.1038/jid.2011.169
40.
KocherT, PekingP, KlauseggerA, et al.Cut and paste: Efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR/Cas9 nickases. Mol Ther. 2017; 25:2585–2598. DOI: 10.1016/j.ymthe.2017.08.015
41.
OhSW, LeeJS, KimMY, et al.Novel keratin 5 mutations in epidermolysis bullosa simplex: Cases with unusual genotype-phenotype correlation. J Dermatol Sci. 2007; 48:229–232. DOI: 10.1016/j.jdermsci.2007.07.014
42.
BchetniaM, LacroixJ, FarezT, et al.Reduction in keratin aggregates in epidermolysis bullosa simplex keratinocytes after pretreatment with trimethylamine N-oxide. Exp Dermatol. 2016; 25:229–230. DOI: 10.1111/exd.12821
43.
RabaiA, ReisserL, Reina-San-MartinB, et al.Allele-specific CRISPR/Cas9 correction of a heterozygous DNM2 mutation rescues centronuclear myopathy cell phenotypes. Mol Ther Nucleic Acids. 2019; 16:246–256. DOI: 10.1016/j.omtn.2019.02.019
44.
KrogerC, LoschkeF, SchwarzN, et al.Keratins control intercellular adhesion involving PKC-alpha-mediated desmoplakin phosphorylation. J Cell Biol. 2013; 201:681–692. DOI: 10.1083/jcb.201208162
45.
SimpsonCL, PatelDM, GreenKJ. Deconstructing the skin: Cytoarchitectural determinants of epidermal morphogenesis. Nat Rev Mol Cell Biol. 2011; 12:565–580. DOI: 10.1038/nrm3175
46.
LiovicM, D'AlessandroM, Tomic-CanicM, et al.Severe keratin 5 and 14 mutations induce down-regulation of junction proteins in keratinocytes. Exp Cell Res. 2009; 315:2995–3003. DOI: 10.1016/j.yexcr.2009.07.013
47.
HolmesJHt, MolnarJA, ShuppJW, et al.Demonstration of the safety and effectiveness of the RECELL((R)) System combined with split-thickness meshed autografts for the reduction of donor skin to treat mixed-depth burn injuries. Burns. 2019; 45:772–782. DOI: 10.1016/j.burns.2018.11.002
48.
PeirceSC, Carolan-ReesG. ReCell® spray-on skin system for treating skin loss, scarring and depigmentation after burn injury: A NICE medical technology guidance. Appl Health Econ Health Policy. 2019; 17:131–141. DOI: 10.1007/s40258-018-00457-0
49.
RenJ, LiuJ, YuN, et al. The use of noncultured regenerative epithelial suspension for improving skin color and scars: A report of 8 cases and review of the literature. J Cosmet Dermatol. 2019. DOI: 10.1111/jocd.13071
50.
RabinowitzR, AlmogS, DarnellR, et al.CrisPam: SNP-derived PAM analysis tool for allele-specific targeting of genetic variants using CRISPR-Cas systems. Front Genet. 2020; 11:851. DOI: 10.3389/fgene.2020.00851
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
